Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

Publication date: May 01, 2019

-CVN424’s excellent safety profile helps validate Cerevance’s approach to CNS target selection and drug discovery,” said David H. Margolin, MD, PhD, Senior Vice President for Clinical and Translational Medicine at Cerevance.

-CVN424 acts through a target that is selectively expressed by neurons important in controlling movement and was engineered to achieve excellent CNS penetration with minimal effects on other organs. “

Beyond CVN424, we look forward to advancing a broad pipeline of therapies acting on targets that have not yet been explored for the treatment of CNS disorders. “

Concepts Keywords
Basal Ganglia Friedreich’s ataxia
Brain Substantia nigra
Central Nervous System Neurodegeneration
Chief Executive Officer Neuron
CNS Disorders Dopamine receptor
Discovery Stage Dopamine
Dopamine Receptor D2 Neurotransmitters
Dopaminergic Nervous system
Dyskinesia Organ systems
ECG Branches of biology
Medium Spiny Neurons Side dyskinesia
Neurodegenerative Diseases Pharmaceutical
Neurons
Parkinson
Pharmaceutical Company
PhD
Pipeline
Placebo
Post Mortem
Vice President
Vital Signs

Semantics

Type Source Name
gene UNIPROT LARGE1
disease MESH central nervous system diseases
pathway BSID Neurodegenerative Diseases
disease MESH neurodegenerative diseases
gene UNIPROT SLC35G1
disease MESH dyskinesia
drug DRUGBANK Dopamine
gene UNIPROT PDC
disease MESH ECG

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *